Revolution Medicines (NASDAQ:RVMD – Get Free Report)‘s stock had its “buy” rating restated by HC Wainwright in a report released on Tuesday, Benzinga reports. They currently have a $350.00 price objective on the stock. HC Wainwright‘s target price would indicate a potential upside of 119.00% from the stock’s current price.
A number of other analysts also recently weighed in on the company. William Blair began coverage on Revolution Medicines in a report on Friday, October 16th. They set an “outperform” rating for the company. Wolfe Research reissued an “outperform” rating and issued a $220.00 price objective on shares of Revolution Medicines in a research note on Monday, August 10th. Morgan Stanley cut their target price on Revolution Medicines from $272.00 to $247.00 and set an “overweight” rating on the stock in a research report on Friday, November 13th. Evercore restated an “outperform” rating and set a $320.00 target price on shares of Revolution Medicines in a research report on Thursday, August 27th. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $248.00 target price on shares of Revolution Medicines in a research note on Thursday, August 27th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Revolution Medicines currently has an average rating of “Moderate Buy” and a consensus target price of $262.75.
Read Our Latest Stock Analysis on RVMD
Revolution Medicines Price Performance
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($1.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.35) by $0.45. The firm had revenue of $197.56 million during the quarter, compared to analyst estimates of $25.58 million. During the same quarter in the previous year, the firm earned ($1.61) EPS. On average, sell-side analysts forecast that Revolution Medicines will post -7.41 EPS for the current year.
Insider Activity at Revolution Medicines
In related news, insider Mark Goldsmith sold 80,000 shares of the business’s stock in a transaction on Friday, August 21st. The shares were sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the transaction, the insider owned 267,330 shares in the company, valued at $55,925,436. The trade was a 23.03% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Stephen Kelsey sold 92,531 shares of the stock in a transaction on Friday, September 11th. The stock was sold at an average price of $202.36, for a total transaction of $18,724,573.16. Following the transaction, the insider directly owned 291,876 shares in the company, valued at approximately $59,064,027.36. This represents a 24.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 353,901 shares of company stock worth $70,706,418 over the last ninety days. 7.60% of the stock is owned by corporate insiders.
Hedge Funds Weigh In On Revolution Medicines
Institutional investors have recently made changes to their positions in the stock. Burkett Financial Services LLC acquired a new stake in shares of Revolution Medicines in the 3rd quarter valued at about $27,000. Contravisory Investment Management Inc. acquired a new position in Revolution Medicines during the 2nd quarter worth approximately $32,000. ABS Investment Management LLC bought a new position in Revolution Medicines in the second quarter worth approximately $337,104,000. Johnson Financial Group Inc. bought a new position in Revolution Medicines in the second quarter worth approximately $37,000. Finally, Mather Group LLC. bought a new position in Revolution Medicines in the third quarter worth approximately $41,000. Institutional investors and hedge funds own 94.34% of the company’s stock.
Revolution Medicines Company Profile
Revolution Medicines, Inc. is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers. The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.
Further Reading
- Five stocks we like better than Revolution Medicines
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
- TJX Stock Flashes a Strong Bullish Signal as Its $3 Billion Buyback Plan Takes Shape
- Viking’s Low-Water Miss Looks Like a Buy-the-Dip Opportunity
- Why Amazon Wants the Chips and Blackstone Wants the Buildings
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
